

Press Release

STADA and SBP Group launch strategic biosimilars partnership, including a biosimilar to Keytruda

- STADA and Sino Biopharmaceutical Limited (SBP Group) subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) enter into an exclusive partnership to expand patient access to biosimilar medicines across multiple territories
- The collaboration includes pembrolizumab, a proposed biosimilar to US\$30bn+ Keytruda® reference brand for various cancer indications, as well as options to add up to three additional biosimilar molecules across oncology and immunology indications
- CTTQ will lead development, manufacturing and supply; STADA secures exclusive commercial rights across the EU, Switzerland, the UK, and Commonwealth of Independent States (CIS), plus options for the US and selected other territories

Bad Vilbel, Germany/Nanjing, China – 28 September 2026 – STADA Arzneimittel AG, a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty pharmaceuticals, and China-based multinational pharma group SBP Group, through its core innovative pharmaceutical subsidiary CTTQ, today announced a strategic biosimilars partnership designed to significantly broaden patient access to high-value biological medicines in key markets.

The collaboration comprises CTTQ developing, manufacturing and supplying biosimilar candidates for which STADA will hold the marketing authorizations and have exclusive sales and marketing rights in the European Union, Switzerland, the United Kingdom and the

Commonwealth of Independent States (CIS). Furthermore, STADA will hold options for the US and Gulf Cooperation Council (GCC) member states.

Included in the collaboration, which contains milestones and profit-share provisions, is the molecule TQB3570, along with a framework to add up to three further molecules. TQB3570 is a proposed pembrolizumab biosimilar to the Keytruda® reference product, a PD-1 checkpoint inhibitor which in 2025 generated global sales in excess of US\$30 billion¹ across a broad range of oncology indications. Pembrolizumab, including quality-assured biosimilars, is included in the World Health Organization (WHO) Model List of Essential Medicines².

STADA CEO Peter Goldschmidt commented: "Partnering with SBP Group and CTTQ on pembrolizumab and further molecules accelerates STADA's growth in biosimilars. Over almost two decades, we have built a robust franchise with 11 approved biosimilars across diverse therapeutic areas through a partner-of-choice strategy, and this agreement further accelerates that trajectory. The strong international partnerships and numerous launches that SBP Group and CTTQ have already achieved across multiple therapeutic classes will support our joint drive to broaden patient access through competition, not least to the world's best-selling biologic."

"SBP Group's recent out-licensing agreements reflect growing recognition of our innovation capabilities. Our collaboration with STADA builds on this momentum, bringing our expertise in biologics development, manufacturing and quality to a broader international stage," said Eric Tse, CEO of SBP Group. "With its long-established commercial infrastructure, deep market understanding and strong presence in Europe, Eurasia and the Middle East, STADA is the ideal partner to help realize the potential of our oncology and immunology biosimilar

¹ [Merck & Co 10-K Annual Report, page 132](#)

² [The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list](#)



candidates. Together, we are advancing our globalization strategy and laying the foundation for wider patient access to high-quality biologic medicines.”

CTTQ’s TQB3570 pembrolizumab biosimilar candidate is currently in development, with a strategy to secure marketing authorizations ahead of biosimilar market formation in key territories. The company already has eight biosimilars approved in China, with several more in development, and is building on the group’s strong track record of out-licensing and regional collaborations for innovative drugs to globalize its biosimilars portfolio through proven partners such as STADA. In doing so, it is leveraging its innovation capabilities and large-scale manufacturing advantages, with a current biologics manufacturing capacity of 126,000 liters³.

STADA’s Chief Commercial Officer, Bryan Kim stated: “Our thorough global market and partner evaluation has identified CTTQ as an ideal long-term partner. Its impressive research and development capabilities are fully integrated with a dedicated manufacturing network that boasts a strong regulatory compliance record and substantial commercial-scale biologics manufacturing capacity. Coupled with STADA’s commercial reach and tender, market-access and medical capabilities, as well as our near 20 years of biosimilars experience and our leading position in Europe across a broad array of molecules, this partnership positions us strongly to compete in future biosimilar markets.”

About STADA

STADA is headquartered in Bad Vilbel, Germany. The group focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA sells its products in over 100 countries. In financial year 2025, STADA achieved group sales of € 4,296 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 961 million. As of 31 December 2025, STADA employed 11,670 people worldwide.

³ Of which 40,000L is under construction



About CTTQ/SBP Group

Chia Tai Tianqing Pharmaceutical Group ("CTTQ") is a core subsidiary of Sino Biopharmaceutical Limited (SBP Group, HKEX: 1177), focused on the research and development, manufacturing and commercialization of innovative and high-quality medicines. Headquartered in China, CTTQ has grown into an innovative pharmaceutical group renowned in oncology, hepatology and respiratory therapeutics, dedicated to continuously providing patients with safe, effective and affordable treatment options.

STADA information for journalists

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18, 61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.com

Or visit us via our website at <https://www.stada.com/media/newsroom>

Follow [@StadaGroup](#) on LinkedIn

STADA information for capital market participants

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18, 61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us via our website at <https://www.stada.com/investor-relations>

SBP & CTTQ media/IR contact information

E-mail: pr@sbpgroup.com

Or visit us via our website: <https://www.sbpgroup.com>